List of works - Dharminder Chauhan

NF-kappa B as a therapeutic target in multiple myeloma

scientific article

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

scientific article

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

scientific article

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

scientific article

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

scientific article published in June 2002

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

scientific article

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

scientific article published on 7 November 2002

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

scientific article published on 26 September 2002

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

scientific article published in August 2002

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

scientific article published on 17 January 2006

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

scientific article published on 12 May 2009

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

scientific article

Antimyeloma activity of heat shock protein-90 inhibition.

scientific article published on 18 October 2005

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application

scientific article

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

scientific article published on 25 September 2003

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

scientific article

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

scientific article

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

scientific article published on 16 January 2003

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

scientific article published on July 2006

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

scientific article

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

scientific article published on December 2005

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

scientific article

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

scientific article published on 19 August 2004

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

scientific article

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

scientific article

Proteasome inhibitor therapy in multiple myeloma

scientific article

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

scientific article

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

scientific article published on February 2002

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

scientific article

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

scientific article

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

scientific article published in November 2003

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

scientific article published on 24 June 2004

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

scientific article

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

scientific article published on April 2004

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

scientific article published on December 2007

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

scientific article published on 10 October 2006

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

scientific article published on 01 January 2003

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

scientific article published on 01 October 2006

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

scientific article published on September 2007

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

scientific article published on September 2003

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

scientific article published on 5 September 2002

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

scientific article published on September 2005

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

scientific article published on July 2002

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

scientific article published in August 2005

The malignant clone and the bone-marrow environment

scientific article published on December 2007

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

scientific article

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

scientific article published on April 24, 2003

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

scientific article published on 11 December 2003

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

scientific article

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

scientific article

List of works by Dharminder Chauhan

NF-kappa B as a therapeutic target in multiple myeloma

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

Antimyeloma activity of heat shock protein-90 inhibition.

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

Proteasome inhibitor therapy in multiple myeloma

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

The malignant clone and the bone-marrow environment

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.